TAK-500

Overview

TAK-500 is an investigational agonist antibody targeting 4-1BB (TNFRSF9), a T-cell co-stimulatory receptor. It is evaluated in nasopharyngeal carcinoma (NPC) and other solid tumors.

Evidence in the corpus

• TAK-500 anti-4-1BB agonist listed among T-cell co-stimulatory receptor agonists (alongside BAT6026 anti-OX40, ADG106 anti-4-1BB) evaluated in phase I in NPC; no significant NPC activity reported to date PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.